Carmine N. Stengone insider trades

Open-market stock purchases and sales by Carmine N. Stengone, CEO and President at Contineum Therapeutics, Inc, from SEC Form 4 filings since Sep 29, 2023.

Track record: 0% of 1 scored buy are up 5% or more since purchase, averaging -36%.

Recent trades

DateStockTradeValue
Sep 8, 2026CTNM Contineum Therapeutics, IncSold$41.1K
Sep 8, 2026CTNM Contineum Therapeutics, IncBought (not open market)$2.5K
Sep 8, 2026CTNM Contineum Therapeutics, IncBought (not open market)—
Aug 3, 2026CTNM Contineum Therapeutics, IncSold$40K
Aug 3, 2026CTNM Contineum Therapeutics, IncBought (not open market)$2.5K
Aug 3, 2026CTNM Contineum Therapeutics, IncBought (not open market)—
Jul 8, 2026CTNM Contineum Therapeutics, IncSold$40K
Jul 8, 2026CTNM Contineum Therapeutics, IncBought (not open market)—
Jul 8, 2026CTNM Contineum Therapeutics, IncBought (not open market)$2.5K
Jun 30, 2026CTNM Contineum Therapeutics, IncSold$160K
Jun 30, 2026CTNM Contineum Therapeutics, IncBought (not open market)$7.6K
Jun 30, 2026CTNM Contineum Therapeutics, IncBought (not open market)$3.1K
Jun 30, 2026CTNM Contineum Therapeutics, IncBought (not open market)—
Jun 30, 2026CTNM Contineum Therapeutics, IncBought (not open market)—
Jun 10, 2026KPRX Kiora Pharmaceuticals IncBought (not open market)—
Feb 25, 2026CTNM Contineum Therapeutics, IncBought (not open market)—
Feb 25, 2026CTNM Contineum Therapeutics, IncSold$43.2K
Feb 24, 2026CTNM Contineum Therapeutics, IncBought (not open market)—
Feb 24, 2026CTNM Contineum Therapeutics, IncSold$70.5K
Feb 11, 2026CTNM Contineum Therapeutics, IncSold$6.4K
Feb 11, 2026CTNM Contineum Therapeutics, IncBought (not open market)—
Jan 30, 2026CTNM Contineum Therapeutics, IncBought (not open market)—

Companies traded

  • CTNM Contineum Therapeutics, Inc: 7 sales, last Sep 8, 2026
  • KPRX Kiora Pharmaceuticals Inc: 1 buy, last Jun 10, 2026

Get free alerts when Carmine N. Stengone files a new trade →